Managing a diagnosis of glioma during pregnancy or guiding conception after brain tumor therapy represents one of the most intricate challenges in modern neuro-oncology and obstetrics. Clinicians routinely face difficult decisions regarding the safety of neurosurgical intervention, radiation timing, and cytotoxic exposure. Moreover, physiological changes during gestation can obscure intracranial symptoms or alter drug pharmacokinetics. A retrospective study led by Valerius and colleagues provides critical clinical insight into these scenarios, shedding light on maternal stability and fetal outcomes across distinct clinical cohorts.

Clinical Dynamics of Glioma During Pregnancy

A new diagnosis of intracranial neoplasia during gestation demands prompt, risk-stratified decision-making. Historically, oncologists and obstetricians lacked robust datasets to guide the delicate balance between maternal oncologic urgency and fetal preservation. The investigation evaluated patients diagnosed either during pregnancy (Cohort A) or prior to conception (Cohort B). Among the evaluated cases, tumors spanned both high-grade and low-grade histologies, reflecting a diverse clinical population. Consequently, clinicians must tailor diagnostic workups, preferring non-contrast magnetic resonance imaging to assess tumor burden while avoiding potentially harmful ionizing radiation and gadolinium-based contrast agents whenever feasible.

Maternal and Obstetric Management During Active Disease

For patients diagnosed with glioma during pregnancy, treatment strategies must prioritize maternal stabilization without imposing undue fetal risk. In the cohort presenting during active gestation, seven out of eight women underwent definitive glioma therapy before delivery. Notably, these interventions did not trigger severe maternal obstetric complications, and every pregnancy in this group culminated in the successful delivery of a healthy neonate. Therefore, surgical resection or urgent therapeutic intervention during the second or early third trimester appears feasible when supported by specialized maternal-fetal medicine teams. In addition, tight hemodynamic control and tailored neuroanesthetic protocols play pivotal roles in securing these positive maternal and fetal trajectories.

Post-Treatment Conception and Offspring Safety

Female cancer survivors of reproductive age frequently seek clarity regarding the safety of subsequent pregnancy. In the post-diagnosis group, thirteen patients accounted for eighteen completed pregnancies. Encouragingly, most maternal courses remained stable throughout gestation. However, antepartum seizures complicated three of the eighteen pregnancies, underscoring the critical need for vigilant neurological monitoring. Plasma volume expansion and accelerated hepatic clearance during gestation frequently lower serum antiepileptic drug concentrations. As a result, multidisciplinary care teams must implement proactive therapeutic drug monitoring to prevent breakthrough seizures that could compromise placental perfusion and maternal safety.

Evaluating Anatomic Findings and Chemotherapy Exposure

An important finding from this clinical series centers on offspring health following maternal antineoplastic exposure. Childhood assessments revealed functionally inconsequential anatomic abnormalities in five out of eighteen offspring born to mothers treated before conception. Specifically, these minor anatomical variations occurred in 31% of children with maternal temozolomide exposure, compared to 20% in unexposed offspring. Although these structural variations did not cause long-term functional impairment or developmental delays, they highlight the value of clear preconception counseling. Clinicians should thoroughly discuss these observations with patients when planning family expansion after alkylating chemotherapy regimens.

Multidisciplinary Care and Preconception Counseling Pathways

Optimal outcomes for patients with brain tumors require seamless coordination across neurosurgery, neuro-oncology, neurology, and high-risk obstetrics. When counseling patients on post-treatment conception, clinicians must establish oncologic stability over a sustained observation period. Furthermore, practitioners should optimize antiepileptic regimens by transitioning patients away from high-risk teratogenic agents prior to conception whenever possible. In addition, supplemental high-dose folic acid should precede pregnancy to reduce neural tube defect risks. Routine surveillance imaging and serial fetal anatomical ultrasonography collectively ensure early identification of both maternal intracranial shifts and fetal developmental milestones.

Translating Retrospective Evidence into Obstetric Practice

Ultimately, this landmark series reinforces that pregnancy remains achievable and generally safe for women diagnosed with or treated for gliomas. While active disease necessitates prompt multidisciplinary intervention, necessary neurosurgical treatments can proceed safely during gestation. Moreover, post-treatment conception demonstrates favorable overall maternal and neonatal survival, despite a slight predisposition toward antepartum seizures and minor structural variations. By standardizing surveillance protocols, monitoring antiepileptic drug levels, and engaging in open preconception dialogues, healthcare providers can confidently navigate the intersecting complexities of neuro-oncology and maternal-fetal medicine.

Frequently Asked Questions

How does active glioma treatment impact delivery and fetal safety?

Active glioma treatment during pregnancy, including neurosurgery and selective systemic interventions, generally yields favorable neonatal outcomes when managed by experienced teams. However, clinicians must carefully time interventions across trimesters. In most documented cases, pregnant individuals who undergo necessary neurosurgical resections deliver healthy full-term neonates without experiencing life-threatening obstetric or oncologic complications.

What are the risks of conceiving after completing glioma therapy?

Conception following glioma therapy is associated with overall positive outcomes, though minor anatomic variations may appear in offspring. Furthermore, maternal seizures represent the primary antepartum complication. Multidisciplinary pre-conceptional counseling remains essential to evaluate oncologic stability, review previous exposure to alkylating agents, and optimize antiepileptic drug regimens before pregnancy occurs.

How should clinicians monitor pregnant patients with a history of glioma?

Clinicians should conduct close multidisciplinary monitoring throughout gestation, involving neuro-oncologists, maternal-fetal medicine specialists, and neurologists. Regular neuro-imaging without gadolinium contrast helps detect disease progression safely. Additionally, practitioners must maintain vigilant therapeutic drug monitoring for antiepileptic medications because physiological pregnancy changes often alter plasma drug concentrations and increase seizure vulnerability.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Valerius AR et al. Pregnancy and neonatal outcomes in patients treated for glioma before or during pregnancy: a single-institution retrospective series. J Neurooncol. 2026 Aug 27. doi: 10.1007/s11060-026-05765-3. PMID: 42658311.
2. Peeters S, Pages M, Gauchotte G, et al. Interactions between glioma and pregnancy: Insight from a 52-case multicenter series. J Neurosurg. 2018;131(1):1-10. doi:10.3171/2018.1.JNS172421.
3. Shireman JM, Distler E, Dey M. Impact of pregnancy on the treatment and outcomes of glioma: a cohort study. J Neurooncol. 2025;171(2):245-253. doi:10.1007/s11060-024-04891-w.